Economics

This channel highlights factors that impact hospital and healthcare economics and revenue. This includes news on healthcare policies, reimbursement, marketing, business plans, mergers and acquisitions, supply chain, salaries, staffing, and the implementation of a cost-effective environment for patients and providers.

Thumbnail

Cardiologist agrees to $5.8M settlement for implanting dozens of unnecessary stents

A seven-years long whistleblower lawsuit against Kansas cardiologist Joseph Galichia ended May 30 with a $5.8 million settlement, the Wichita Eagle reported.

Thumbnail

AFib market expected to reach $14.7B by 2026

The atrial fibrillation market is projected to reach $14.68 billion by 2026, according to recent estimates from market research company Reports and Data.

Thumbnail

Immigrant with heart failure, CAD deported without adequate access to healthcare

An undocumented immigrant living in Brooklyn, N.Y., was deported to his home country last Wednesday after ICE officials ignored attorneys’ requests to keep him in the U.S. for much-needed medical treatment, WNYC reported.

Thumbnail

ACC names 1st-ever director of diversity and inclusion

Ranna Parekh, MD, MPH, has been named by the American College of Cardiology as its first director of diversity and inclusion, according to a statement issued by the College May 23.

Thumbnail

Andrea Russo inducted as HRS president

Cardiologist Andrea M. Russo, MD, took the reins of the Heart Rhythm Society as president this month after an induction ceremony at the organization’s annual meeting in San Francisco.

Thumbnail

Federal judge: Illegal actions by FDA fueled e-cig epidemic

A federal judge on May 15 ruled the FDA acted illegally more than a year and a half ago when it allowed e-cigarette products geared toward kids and teens to remain on the market prior to and during the agency’s approval process.

Thumbnail

New rule allows physicians to refuse care on grounds of religious, moral beliefs

A new rule issued by HHS under the Trump administration allows physicians, hospitals and insurers to refuse care to certain patients on grounds of religious beliefs—something a New York Times columnist says could lead to “chaos in healthcare."

Thumbnail

From Concept to Clearance: Why It’s So Expensive to Develop New CV Drugs

Earning approval to use a new cardiovascular drug in the clinical setting can cost 100+ times the average of bringing other medications to market.  

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.